Molecular and Clinical Oncology分子与临床肿瘤学
Molecular and Clinical Oncology(英文缩写 MOL CLIN ONCOL),ISSN 2049-9450,eISSN 2049-9469,中文译名:分子与临床肿瘤学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 未收录 | N/A |
| 2022 | 1.200 | N/A |
| 2023 | 1.400 | Q4 |
| 2024 | 1.400 | Q4 |
| 2025 | 1.900 | Q4 |
Molecular and Clinical Oncology 最新收录文献
-
1. Cumulative cytotoxic chemotherapy exposure after the introduction of PARP inhibitors in advanced high-grade serous tubo-ovarian and primary peritoneal carcinoma: A descriptive single-center historical cohort study.
PMID:日期:2026-09-03The present study aimed to describe real-world treatment patterns, cumulative exposure to cytotoxic chemotherapy, and exploratory survival outcomes before and after the clinical introduction of poly(ADP-ribose) polymerase (PARP) inhibitors in patients with stage III-IV high-grade serous ovarian, fallopian tube or primary peritoneal carcinoma. The medical records of patients with stage III-IV high-grade serous ovarian, fallopian tube or primary peritoneal carcinoma who received chemotherapy at Jichi Medical University Saitama Medical Center (Saitama, Japan) between January 2009 and August 2023 were retrospectively reviewed. The primary outcomes were the number of chemotherapy regimens and the cumulative number of cytotoxic chemotherapy cycles. Overall survival was evaluated as an exploratory secondary outcome. The final cohort included 86 patients, comprising 48 patients in the PARP inhibitor-untreated group and 38 patients in the PARP inhibitor-treated group. The groups exhibited differences in several baseline characteristics, including International Federation of Gynecology and Obstetrics stage, receipt of neoadjuvant chemotherapy and cytoreduction status. The cumulative number of cytotoxic chemotherapy cycles was significantly higher in the PARP inhibitor-untreated group than in the PARP inhibitor-treated group [median, 18.5 (range, 6-49) vs. 12.0 (range, 5-45); P=0.020], whereas the number of chemotherapy regimens did not differ significantly [median, 3 (range, 1-7) vs. 2 (range, 1-8); P=0.081]. Overall survival appeared to be longer in the PARP inhibitor-treated group; however, this finding should be interpreted with caution due to the retrospective historical design and baseline imbalances. In this descriptive single-center cohort restricted to advanced high-grade serous ovarian, fallopian tube or primary peritoneal carcinoma, the clinical introduction of PARP inhibitors was associated with lower cumulative exposure to cytotoxic chemotherapy. No causal inference regarding survival benefits could be made due to substantial treatment-selection bias and baseline imbalances.
-
2. Clinicopathological features and prognoses of HER-2-positive gastric cancer.
PMID:日期:2026-09-03The present study aimed to investigate the clinicopathological characteristics of human epidermal growth factor receptor-2 (HER-2)-positive gastric cancer and their association with HER-2 protein expression levels and prognosis. In total, 99 patients diagnosed with HER-2-positive gastric cancer who underwent radical gastrectomy were included in the study. χ² testing explored the association between HER-2 protein expression and clinical features. Disease-free survival (DFS) and overall survival (OS) were evaluated through Kaplan-Meier survival curves. Univariate and multivariate Cox regression analyses were performed to evaluate the impact of clinical variables on DFS and OS. HER-2 protein expression, tumor size, tumor invasion, lymph node metastasis, Tumor-Node-Metastasis stage, perineural invasion (PNI) and lymphovascular invasion (LVI) were associated with inferior DFS. HER-2 protein expression emerged as an independent prognostic factor of DFS in HER-2-positive gastric cancer, but showed no association with OS. Compared with HER-2 immunhistochemistry (IHC) 2+ groups, patients with HER-2 IHC 3+ exhibited a higher prevalence of PNI and LVI, a shorter median DFS time, and a lower tumor-free survival rate at 1, 3 and 5 years post-surgery. In conclusion, HER-2 is a significant negative prognostic factor, associated with a poorer DFS time, although data on OS remain limited. HER-2 IHC 3+ gastric cancer is characterized by a higher prevalence of PNI and LVI.
-
3. Application of artificial intelligence in early warning, diagnosis and precise treatment of head and neck tumors (Review).
PMID:日期:2026-08-21Head and neck tumors face challenges in clinical practice such as difficulty in early warning, delayed diagnosis, and insufficient individualized treatment due to their complex anatomical structure and insidious early symptoms. In recent years, the rapid development of artificial intelligence (AI) technology in the medical field has brought new opportunities for the diagnosis and treatment of head and neck tumors. With its powerful data processing and pattern recognition capabilities, it provides new ideas for solving problems related to early cancer diagnosis, planning optimal treatment strategies, and predicting patient survival likelihood. However, the clinical translation of AI models still faces bottlenecks such as data standardization, model generalization, and ethical compliance. In the future, it is necessary to build a multi-center collaboration platform and develop interpretable algorithms to promote the deep integration of AI technology and clinical practice. The present review analyzes and summarizes the latest progress of AI in head and neck malignant tumors and explores its application and development prospects in cancer research and clinical practice.
-
4. Tumor microenvironment-mediated resistance to immune checkpoint inhibitors in non-small cell lung cancer: Mechanisms, combination strategies and clinical perspectives (Review).
PMID:日期:2026-08-13Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-associated mortality worldwide. Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1 (PD-L1) and cytotoxic T lymphocyte-associated protein 4 have transformed the treatment landscape of NSCLC. However, primary and acquired resistance limit durable clinical benefit. The current review article aimed to summarize tumor microenvironment-mediated resistance as an interconnected biological process rather than a collection of isolated factors. Immunosuppressive myeloid populations, regulatory lymphocytes, cancer-associated fibroblasts, extracellular matrix remodeling, vascular endothelial growth factor-driven vascular dysfunction, hypoxia, transforming growth factor-β signaling and metabolic reprogramming cooperate with defects in antigen presentation, dysregulation of serine/threonine kinase 11/Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor 2/stimulator of interferon genes and oncogenic driver signaling to generate immune-desert (minimal immune cell infiltration), immune-excluded (immune cells retained outside tumors) or exhausted immune-inflamed (immune-cell infiltration with functional exhaustion) phenotypes. The present review also critically evaluated combination therapeutic strategies, distinguishing phase III-supported standards from early-phase clinical or preclinical approaches, while highlighting considerations associated with patient selection, toxicity and the evolving regulatory context. Finally, an operational biomarker framework integrating PD-L1 expression, tumor mutational burden, interferon γ-associated signatures, spatial profiling, circulating tumor DNA, exosomal biomarkers and microbiome features was proposed to guide precision immunotherapy in NSCLC.
-
5. Hearing impairment following radiotherapy in patients with nasopharyngeal carcinoma (Review).
PMID:日期:2026-08-11Nasopharyngeal carcinoma (NPC) is a geographically prevalent malignant mucosal tumor endemic to southern China and Southeast Asia. Radiotherapy constitutes the core curative treatment for NPC, often combined with chemotherapy or targeted therapy in clinical practice. Hearing loss is a common radiotherapy-related complication caused by radiation damage to middle ear structures, inner ear cells and auditory nerves, with a variable incidence affected by treatment protocols and patient characteristics. Such auditory dysfunction negatively impacts patients' cognition, emotion and quality of life. However, systematic summaries of subjective evaluation tools and targeted non-surgical rehabilitation strategies for radiotherapy-induced hearing impairment remain insufficient. Accordingly, this review aims to elaborate on the classification, multidimensional clinical impacts, subjective assessment scales, and non-surgical interventions of radiotherapy-related hearing loss, so as to provide evidence-based references for clinical rehabilitation of NPC survivors.
-
6. AXL is associated with STAT3 activation in breast cancer.
PMID:日期:2026-08-06Breast cancer (BC) represents one of the most frequently occurring malignancies and a primary cause of cancer-associated mortality among women globally. AXL, a receptor tyrosine kinase of the TAM family, and signal transducer and activator of transcription 3 (STAT3) are both aberrantly activated in BC and contribute to tumor progression. The present study aimed to investigate the functional association between AXL and STAT3 activation in BC. It was found that the overexpression of AXL in MCF7 and 293T cells enhanced STAT3 phosphorylation and transcriptional activity, whereas AXL knockdown using short hairpin RNA or pharmacological inhibition with R428 suppressed STAT3 activation. AXL overexpression also enhanced the secretion of IL-6, a major upstream activator of STAT3. Bioinformatics analysis of clinical BC datasets (GSE102484, GSE9893 and The Cancer Proteome Atlas) validated a positive correlation between AXL expression and STAT3 signaling activation. Collectively, these findings demonstrate that AXL is associated with STAT3 activation in BC, providing insight into the molecular pathways driving BC progression and uncovering candidate therapeutic targets.
-
7. Prognostic value of pre- and post-treatment neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratios in nasopharyngeal carcinoma.
PMID:日期:2026-07-31Blood cell count ratios are useful prognostic indicators in cancer. The present retrospective study evaluated the levels of the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) across different treatment phases and their potential prognostic value in nasopharyngeal carcinoma. A total of 99 patients were treated with induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT). Biomarkers were assessed at three separate time points: Pre-IC, pre-CCRT and post-radiation therapy (RT). Results indicated that the NLR and PLR values were higher, while the LMR values were lower at later chronological time points, particularly post-RT. Post-RT, higher NLR and PLR levels and a lower LMR level were observed in non-survivors. Being ≥60 years old was associated with lower odds of elevated PLR post-RT and experiencing weight loss ≥7.5% predicted increased NLR post-RT. Elevated pre-IC and post-RT PLR was associated with reduced 5-year overall survival. Multivariate analysis, although limited by the small number of events (n=15), identified PLR pre-IC and advanced nodal stage (N3) as independent mortality predictors. PLR pre-IC and N3 stage may therefore serve as preliminary independent predictors of poor prognosis, supporting the use of inflammatory biomarkers for risk stratification. Despite this, prospective external validation in larger cohorts is required.
-
8. Short-term and long-term outcomes of non-tracheal intubation anesthesia in thoracoscopic lobectomy for lung cancer: A systematic review and meta-analysis.
8. 非气管插管麻醉在肺癌胸腔镜肺叶切除术中的短期和长期 outcomes：一项系统综述和荟萃分析PMID:日期:2026-07-28[中文摘要] 本研究通过系统评价和荟萃分析，比较了非插管视频辅助胸腔镜手术（NIVATS）与插管视频辅助胸腔镜手术（IVATS）在肺癌肺叶切除术中的疗效和安全性。共检索了六个电子数据库，纳入截至2024年10月发表的比较NIVATS与IVATS的研究。经过严格筛选和质量评价，系统分析了18项研究的围手术期结局和术后并发症，包括三项随机对照试验、六项倾向性评分匹配研究和九项回顾性研究。共2，313例肺癌患者接受了胸腔镜肺叶切除术，其中1，082例接受NIVATS，1，231例接受IVATS。结果显示，与IVATS组相比，NIVATS显著缩短了手术时间[均数差（MD）=11.02；95%置信区间（CI），-18.78至-3.27]、减少了淋巴结清扫数量（MD=-0.67；95%CI，-1.24至-0.11）、缩短了麻醉苏醒时间（MD=-22.88；95%CI，-33.13至-12.64）、进食时间（MD=-4.53；95%CI，-5.74至-3.32）、胸腔引流管留置时间（MD=-0.68；95%CI，-1.16至-0.21）和住院时间（MD=-1.16；95%CI，-1.57至-0.74）。NIVATS组的总并发症[比值比（OR）=0.53；95%CI，0.31至0.90]，尤其是咽喉痛（OR=0.18；95%CI，0.10至0.33）和肺炎（OR=0.54；95%CI=0.30至0.98）显著低于IVATS组。NIVATS患者中4.33%发生再次插管，而中转开胸率在NIVATS组（0.69%）和IVATS组（0.60%）中均较低且相似。重要的是，NIVATS与总生存期[风险比（HR）=0.63；95%CI，0.40至0.98]和无复发生存期（HR=0.62；95%CI，0.46至0.85）的显著改善相关。麻醉时间、失血量、声音嘶哑、漏气或心律失常方面未观察到显著差异。在加速康复外科框架下，基于现有证据，NIVATS似乎是IVATS一种安全且技术可行的替代方案，具有改善患者结局的潜力。本研究的证据支持其临床推广应用，为知情决策提供了依据。
[英文摘要] The present study compared the efficacy and safety of non-intubated video-assisted thoracoscopic surgery (NIVATS) with intubated video-assisted thoracoscopic surgery (IVATS) for lobectomy in the treatment of lung cancer through a systematic review and meta-analysis. A total of six electronic databases were searched for studies comparing NIVATS and IVATS published up to October 2024. After rigorous screening and quality assessment, perioperative outcomes and postoperative complications were systematically analyzed from 18 studies, comprising three randomized controlled trials, six propensity score-matched studies and nine retrospective studies. A total of 2,313 patients with lung cancer underwent thoracoscopic lobectomy, of whom 1,082 underwent NIVATS and 1,231 underwent IVATS. The results revealed that NIVATS significantly reduced operative time [mean difference (MD)=11.02; 95% confidence interval (CI), -18.78 to -3.27], lymph nodes harvested (MD=-0.67; 95% CI, -1.24 to -0.11), anesthesia waking time (MD=-22.88; 95% CI, -33.13 to -12.64), feeding time (MD=-4.53; 95% CI, -5.74 to -3.32), chest tube indwelling time (MD=-0.68; 95% CI, -1.16 to -0.21) and hospital stay (MD=-1.16; 95% CI, -1.57 to -0.74) compared with the IVATS group. Total complications [odds ratio (OR)=0.53; 95% CI, 0.31 to 0.90], particularly sore throat (OR=0.18; 95% CI, 0.10 to 0.33) and pneumonia (OR=0.54; 95% CI=0.30 to 0.98) were significantly lower in the NIVATS group than in the IVATS group. Re-intubation occurred in 4.33% of NIVATS patients, while conversion to thoracotomy rates were similarly low in the NIVATS (0.69%) and IVATS (0.60%) groups. Importantly, NIVATS was associated with significantly improved overall survival [hazard ratio (HR)=0.63; 95% CI, 0.40 to 0.98] and recurrence-free survival (HR=0.62; 95% CI, 0.46 to 0.85). No significant differences were observed for anesthesia time, blood loss, hoarseness, air leakage or arrhythmia. Under the enhanced recovery after surgery framework, NIVATS appears to be a safe and technically feasible alternative to IVATS, with the potential to improve patient outcomes based on the available evidence. Its clinical adoption is supported by the evidence in the present study, offering a basis for informed decision-making.
-
9. Biology and function of the autotaxin/lysophosphatidic acid axis in cancer (Review).
9. 自分泌运动因子/溶血磷脂酸轴在癌症中的生物学功能（综述）PMID:日期:2026-07-27[中文摘要] 自分泌运动因子（ATX）溶血磷脂酶D已被认定为肿瘤细胞的“自分泌运动因子”。肿瘤微环境（TME）在癌症发生发展中发挥关键作用，ATX作为ATX/溶血磷脂酸（LPA）轴的组成部分，被整合入复杂的分子信号网络之中。该轴尤为重要，因为它激活多条相互重叠的信号转导通路，从而在TME内几乎所有细胞类型中介导多效性作用。ATX/LPA通路具有多种分子和细胞驱动因素，使得由ATX/LPA激活的信号机制成为癌症发生发展中值得研究的重要课题。本综述讨论了ATX/LPA对涉及多种TME组分的三大宏观事件的多种效应：i）炎症与免疫；ii）细胞增殖与代谢；以及iii）侵袭与转移。本综述旨在突出ATX/LPA通路在癌症发病机制中的临床意义。阐明ATX的作用并在炎症循环中阻断该通路，可能为改善癌症治疗开辟新的治疗途径。尽管已有若干综述探讨了癌症中的ATX/LPA轴，但大多数主要聚焦于其在肿瘤生长、迁移和转移中的作用。相比之下，本综述提供了一种更新的、整合性的视角，着重强调2020至2025年间关于ATX/LPA轴在塑造TME免疫代谢格局中作用的最新进展，尤其关注炎症驱动的免疫调节。
[英文摘要] Autotaxin (ATX) lysophospholipase D has been identified as an 'autocrine motility factor' for tumour cells. The tumour microenvironment (TME) serves a critical role in cancer development, with ATX, as a component of the ATX/lysophosphatidic acid (LPA) axis, integrated into a complex network of molecular signalling. This axis is particularly significant because it activates multiple overlapping signal transduction pathways, thereby mediating pleiotropic effects across nearly all cell types within the TME. The ATX/LPA pathway has multiple molecular and cellular drivers, making the signalling mechanisms activated by ATX/LPA an interesting subject for evaluation in cancer development. The present review discusses the multiple effects of ATX/LPA on three macroevents involving several TME components: i) Inflammation and immunity; ii) cellular proliferation and metabolism; and iii) invasion and metastasis. The aim of the present review was to highlight the clinical impact of the ATX/LPA pathways in the pathogenesis of cancer. Clarifying the role of ATX and blocking this pathway in the inflammatory cycle may open novel therapeutic avenues to improve cancer treatment. Although several reviews have addressed the ATX/LPA axis in cancer, most have focused primarily on its roles in tumour growth, migration and metastasis. By contrast, the present review provides an updated, integrative perspective that emphasizes recent advances (2020-2025) regarding the role of the ATX/LPA axis in shaping the immunometabolic landscape of the TME, with particular attention to inflammation-driven immune regulation.
-
10. {"_":"Differentiation therapy targeting indoleamine 2,3-dioxygenase 1 in glioblastoma cells .","i":["in vitro"]}
PMID:日期:2026-07-21Glioblastoma cells strongly express the tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1), which is important in enabling immune evasion. Notably, glioma stem-like cells (GSCs) express higher levels of IDO1 than differentiated glioblastoma cells (DGCs); therefore, it was hypothesized that IDO1 inhibition in GSCs may induce differentiation. The present study used the glioblastoma cell line U-87MG, and newly established GSC lines 0125-GSC and 0222-GSC. A model GSC line, Rev-U-87MG, was created by culturing U-87MG in serum-free medium. Rev-U-87MG-IDO(-) was generated by continuous treatment with an IDO1 inhibitor. The DGC lines 0125-DGC and 0222-DGC were derived by culturing 0125-GSC and 0222-GSC in serum-containing medium. IDO1-inhibited GSC lines 0125-GSC-IDO(-) and 0222-GSC-IDO(-) were generated by continuous IDO1 inhibitor exposure. The expression levels of IDO1 and stem cell markers (Nestin, Nanog and Sox2) were measured by western blotting, and temozolomide sensitivity was evaluated by cell counting. Notably, U-87MG, 0125-DGC and 0222-DGC adhered without sphere formation. By contrast, Rev-U-87MG, 0125-GSC and 0222-GSC formed spheres, whereas IDO1-inhibited cells showed partial adhesion with reduced sphere formation. IDO1 and stem cell marker expression were reduced in all IDO1-inhibited cell lines. Rev-U-87MG exhibited decreased temozolomide sensitivity compared with U-87MG, whereas Rev-U-87MG-IDO(-) showed increased sensitivity. Similarly, 0125-DGC and 0222-DGC were more sensitive than their parent GSC lines, and 0125-GSC-IDO(-) and 0222-GSC-IDO(-) also exhibited enhanced drug sensitivity compared with their parent GSC lines at multiple concentrations. These findings suggest that IDO1 inhibition may induce the differentiation of GSCs and reduce their resistance to temozolomide.